Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status WILMINGTON, Del.--(BUSINESS WIRE)-- ...

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor treatment. The EPIK-B5 study reported a median ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that the U.S. Food and Drug Administration or FDA has approved its Truqap (capivasertib) in combination with Faslodex ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Fosaprepitant for Injection and ...

Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships At the time of the primary PFS analysis, interim ...

Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, has launched Fosaprepitant for Injection and Fulvestrant Injection. “Avenacy has had a strong start to 2024, ...

In a recent update, the National Comprehensive Cancer Network (NCCN) recommended capivasertib combined with fulvestrant for hormone receptor–positive and HER2-negative locally advanced or metastatic ...

NORWOOD, Mass.--(BUSINESS WIRE)--Veramorph LLC (VeraMorph), a science-driven startup developing a novel degradable gel as a solubility-enhancing oral drug delivery technology, has been awarded a Small ...

First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia In this multicenter, ...

A total of 62 patients were initially screened across five study centers for eligibility in this study. Of these, 15 patients were excluded due to various reasons: 10 failed the screening, 3 declined ...